Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 7.89%
March 31, 2026 -2.85%
December 31, 2025 6.83%
September 30, 2025 6.66%
June 30, 2025 7.12%
March 31, 2025 -3.58%
December 31, 2024 6.21%
September 30, 2024 7.45%
June 30, 2024 7.73%
March 31, 2024 3.18%
December 31, 2023 7.40%
September 30, 2023 7.00%
June 30, 2023 6.54%
March 31, 2023 1.89%
December 31, 2022 6.15%
September 30, 2022 1.96%
June 30, 2022 5.57%
March 31, 2022 -0.11%
December 31, 2021 6.92%
September 30, 2021 10.62%
June 30, 2021 7.89%
March 31, 2021 3.29%
December 31, 2020 9.22%
September 30, 2020 8.25%
June 30, 2020 -13.12%
Date Value
March 31, 2020 -2.77%
December 31, 2019 8.22%
September 30, 2019 6.09%
June 30, 2019 7.77%
March 31, 2019 3.27%
December 31, 2018 1.71%
September 30, 2018 6.67%
June 30, 2018 6.65%
March 31, 2018 -0.91%
December 31, 2017 8.01%
September 30, 2017 5.47%
June 30, 2017 6.43%
March 31, 2017 3.02%
December 31, 2016 6.98%
September 30, 2016 6.49%
June 30, 2016 3.98%
March 31, 2016 1.46%
December 31, 2015 5.09%
September 30, 2015 8.70%
June 30, 2015 6.63%
March 31, 2015 -1.07%
December 31, 2014 7.91%
September 30, 2014 9.04%
June 30, 2014 8.98%
March 31, 2014 4.90%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Castle Biosciences, Inc. 74.29%
Lumexa Imaging Holdings, Inc. 11.05%
Quest Diagnostics, Inc. 32.53%
Labcorp Holdings, Inc. 27.71%
OPKO Health, Inc. 37.32%